06.05.2019 Symrise AG  DE000SYM9999

DGAP-News: Symrise acquires Italian biotech company Cutech


 

DGAP-News: Symrise AG / Key word(s): Takeover/Expansion
Symrise acquires Italian biotech company Cutech

06.05.2019 / 14:00
The issuer is solely responsible for the content of this announcement.


  • Adds competitive edge in bio-analytical methods
  • Expands R&D capacities for the efficacy testing of cosmetic ingredients
  • Accelerates the development of active ingredients based on predictive ex vivo models
  • Unique pre-clinical screening services provided to the cosmetic industry

Symrise has signed a contract to acquire the Italian biotech company Cutech in Padua. The enterprise offers unique pre-clinical screening services for cosmetic ingredients and finished formulations. The purchase will expand the expertise of Symrise in the efficacy testing of cosmetic ingredients and open new opportunities for collaboration with partners from scientific institutions. It will also increase the go-to-market speed for novel active ingredients.
 

"Cutech constitutes the perfect fit for Symrise's Cosmetic Ingredients Division. The highly specific R&D and biotechnology capabilities of Cutech optimally complement the research expertise of Symrise", says Dr. Gerhard Schmaus, Head of Global Innovation Cosmetic Ingredients Division at Symrise.
 

"We have decided to closer collaborate with Symrise as both partners can benefit from the union. Symrise acquires considerable know-how in the prediction of the effectiveness of cosmetic ingredients. Cutech will benefit from the broad research base at Symrise and its technological resources. This will lead to a faster development of effective cosmetic ingredients. We look forward with excitement to our joint projects," says Dr. Paolo Pertile, CEO at Cutech.
 

The biotech company, founded in 2002, specializes in unique pre-clinical screening services based on innovative proprietary ex vivo skin, sebaceous gland and hair models. Cutech also contributes IP on natural ingredients, such as micro algae to supplement the Symrise portfolio.
 

"The joining forces of Symrise and Cutech will make the development of new proprietary analysis and prediction models for cosmetic ingredients easier and faster. Such models will strengthen the leadership of Symrise Cosmetics Ingredients and will position it one step ahead of the competition", concludes Eder Ramos, President Cosmetic Ingredient Division. "For our customers, adding pre-clinical testing to our service portfolio will definitely constitute a plus during their product development. In addition it will also enable us to further expand our biotech network, thus accessing new, cutting-edge technologies."
 

Deloitte Financial Advisory S.r.l. is acting as financial advisor to Symrise. Clifford Chance is acting as legal advisor to Symrise. Pirola Pennuto Zei & Associati is acting as legal advisor to Cutech.

 

About Symrise:

Symrise is a global supplier of fragrances, flavorings, food ingredients, cosmetic active ingredients and raw materials, as well as functional ingredients. Its clients include manufacturers of perfumes, cosmetics, food and beverages, the pharmaceutical industry and producers of nutritional supplements and pet food.

Its sales of approximately EUR 3.2 billion in the 2018 fiscal year make Symrise a leading global provider. Headquartered in Holzminden, Germany, the Group is represented with over 100 sites in Europe, Africa, the Middle East, Asia, the United States and Latin America.

Symrise works with its clients to develop new ideas and market-ready concepts for products that form an indispensable part of everyday life. Economic success and corporate responsibility are inextricably linked as part of this process. Symrise - always inspiring more.

 

Media contacts:

Bernhard Kott
Phone: +49 55 31 90-17 21
Email: [email protected]

Christina Witter
Phone: +49 55 31 90-21 82
Email: [email protected]
 

Social media:

twitter.com/symriseag
linkedin.com/company/Symrise
youtube.com/agsymrise
xing.com/companies/symrise

 



06.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Symrise AG
Mühlenfeldstraße 1
37603 Holzminden
Germany
Phone: +49 (0)5531 90 0
E-mail: [email protected]
Internet: www.symrise.com
ISIN: DE000SYM9999, DE000SYM7787, DE000SYM7704
WKN: SYM999
Indices: MDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 807417

 
End of News DGAP News Service

807417  06.05.2019 

fncls.ssp?fn=show_t_gif&application_id=807417&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 2.996,29 3.154,03 3.407,85 3.520,45 3.825,69 4.618,48 4.730,19
EBITDA1,2 630,31 630,52 685,07 742,08 813,62 795,42 851,65
EBITDA-Marge3 21,04 19,99 20,10 21,08 21,27 17,22
EBIT1,4 431,59 433,97 455,35 487,51 558,96 503,98 559,36
EBIT-Marge5 14,40 13,76 13,36 13,85 14,61 10,91 11,83
Jahresüberschuss1 275,65 297,69 297,88 314,95 385,03 290,70 344,94
Netto-Marge6 9,20 9,44 8,74 8,95 10,06 6,29 7,29
Cashflow1,7 396,18 441,79 546,76 635,68 521,56 360,11 719,51
Ergebnis je Aktie8 2,06 2,08 2,12 2,22 2,70 2,00 2,44
Dividende8 0,88 0,90 0,95 0,97 1,02 1,10 0,85
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

INVESTOR-INFORMATIONEN
©boersengefluester.de
Symrise
WKN Kurs in € Einschätzung Börsenwert in Mio. €
SYM999 99,920 Halten 13.966,02
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
29,39 38,24 0,80 44,63
KBV KCV KUV EV/EBITDA
4,02 19,41 2,95 19,53
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,10 1,10 1,10 15.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.04.2024 01.08.2024 24.10.2024 06.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-2,71% 2,29% 0,28% -7,65%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Symrise AG  ISIN: DE000SYM9999 können Sie bei EQS abrufen


Chemie , SYM999 , SY1 , XETR:SY1